Technologies
PDF


WARF: P190021US02

Gene Correction of Pompe Disease and Other Autosomal Recessive Disorders via CRISPR and other RNA-Guided Nucleases


INVENTORS -

Krishanu Saha, Jared Carlson-Stevermer, Lucille Kohlenberg

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in improving gene editing interventions against Pompe disease and other autosomal recessive disorders. UW–Madison researchers have developed a complexed CRISPR-Cas gene editing approach for treating Pompe disease.
OVERVIEWPompe disease is a rare autosomal recessive genetic disease (mutations from both parent carriers have to be inherited by the offspring to see symptoms) that typically affects children during development, but can also present as an adult. Pompe disease is characterized by a lack of functional acid alpha-glucosidase (GAA) enzyme. The lack of GAA leads to a glycogen buildup in cells throughout the body, which results in muscular weakness and wasting. Newborns in which the disease is misdiagnosed rarely survive past one year. Currently, children suffering from the disease are provided with GAA enzyme via biweekly intravenous (IV) infusions, but not all children respond to the treatment.

Gene therapy is an attractive alternative to enzyme replacement treatment for Pompe disease. However, most conventional gene therapy strategies focus on adding extra copies of the normal gene without correcting the preexisting mutations within the cells of the patient. Correcting the preexisting mutation preserves the natural regulation of the gene and can lead to more durable and efficacious treatments with less toxicity from adding extra copies of the gene. Almost 400 mutations to the gene have been identified, complicating gene therapy approaches. Inventors at UW-Madison explored the possibility of correcting mutations on both mutant alleles using CRISPR-Cas to determine whether there was any advantage to that strategy.
THE INVENTIONUW–Madison researchers have developed a complexed CRISPR-Cas system (S1mplex; P170309US01) for treating patients with inherited autosomal recessive conditions. The work focuses on Pompe disease. The inventors identified new guide RNA target sites and repair templates that could be used for gene therapy strategies and cell therapeutic strategies.

The inventors demonstrated successful editing of fibroblast and induced pluripotent stem cells from three Pompe patients at UW Hospital having heterozygous mutations (each allele containing a different mutation, both leading to loss of function of the enzyme). Using their complexed CRISPR-Cas technology markedly increased editing precision (18.4-fold) in two different cell lines (HEK and hPSC), easing concerns about off-target effects. Importantly, rapid glycogen processing improvements were observed after gene correction – 24 hours and 96 hours, respectively.
APPLICATIONS
  • Gene editing of deleterious mutations found in Pompe disease cells
KEY BENEFITS
  • Paired with complexed CRISPR-Cas (S1mplex), precise-to-imprecise editing ratios were improved 18.4-fold.
  • Intervention utilizing multiple gene correction within the same human cell is possible.
  • Rapid improvements in glycogen processing is observed (as short as 24 hours).
Contact Information
For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.